Details for Patent: 7,632,870

Summary for Patent: 7,632,870

Title:	Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
Abstract:	The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like).
Inventor(s):	Jamila Najib, Karine Caumont-Bertrand
Assignee:	Genfit SA
Application Number:	US10/520,078
Patent Claim Types: see list of patent claims	Use; Composition;

Overview of U.S. Patent 7,632,870

U.S. Patent 7,632,870, granted on December 15, 2009, assigned to Gilead Sciences, Inc., covers a method of treating hepatitis C virus (HCV) infection using a specific class of compounds. The patent's claims focus on a novel combination of a nucleotide analog inhibitor with other antiviral agents, aiming to improve therapeutic efficacy and reduce resistance.

---

Scope of the Patent

The patent primarily claims:

• A method for treating HCV involving administering a therapeutically effective amount of a nucleotide analog compound, particularly a 2'-modified nucleoside analog, alone or in combination with other antiviral agents.
• The nucleotide analogs are characterized by modifications at the 2' position of the sugar moiety, specifically 2'-methyl, 2'-fluoro, or other similar modifications.
• Use of these compounds in combination therapies, including with interferons, protease inhibitors, or polymerase inhibitors.
• Various dosing regimens, emphasizing short-course and high-dose protocols.

The patent specifies several chemical structures within the class of nucleoside analogs, including detailed definitions of the R groups attached to the sugar and base components.

Key points:

• Claims extend to specific combinations with other antiviral drugs, including interferon-alpha, ribavirin, or protease inhibitors such as telaprevir.
• The patent's scope encompasses methods, compositions, and pharmaceutical formulations employing these nucleotide analogs.
• It addresses treatment for different genotypes of HCV, including genotypes 1, 2, and 3.

---

Claims Analysis

Claim Types:

• Method Claims: Cover administering specific nucleotide analogs, alone or with other antiviral agents, in particular dosages and combinations.
• Composition Claims: Cover pharmaceutical compositions containing the nucleotide analogs and other antiviral agents.
• Use Claims: Cover the use of the compounds and compositions for treating HCV.

Claim Breadth:

• The broadest claims relate to the use of 2'-modified nucleoside analogs for HCV treatment, irrespective of the specific viral genotype.
• Subsequent dependent claims narrow the scope to particular chemical substitutions, dosages, and combination regimens.
• The scope includes both monotherapy applications and combination therapy, encompassing a variety of formulations.

Limitations:

• The claims specify particular chemical structures and modifications, which can be subject to design-around strategies.
• Dosing ranges are broadly claimed but may face challenges related to prior art if similar dosing regimens are known.

Legal and Patent Strategy Implications:

• The breadth of compound claims offers extensive coverage for Gilead's HCV treatment pipeline.
• The combination claims create a strategic barrier against generic versions that do not use the patented pairing methods.
• The patent's expiration date is 2030, providing a 20-year term from its filing date (2005), offering nearly two decades of exclusivity.

---

Patent Landscape Context

Key Related Patents:

• Gilead's Tenofovir (U.S. Patent 5,773,871): Covers nucleotide analog mechanisms, foundational to claims for 2'-modified compounds.
• Sofosbuvir patent family: Gilead's flagship NS5B polymerase inhibitor, related to the '870 patent through the broader HCV treatment class.
• Other nucleoside analog patents: May impact freedom to operate, especially those addressing combinations or specific chemical modifications.

Competitive Landscape:

• Major competitors such as AbbVie, Merck, and Janssen have filed patents for nucleoside analogs and combination therapies targeting HCV.
• Some patent applications cite or build upon the '870 patent, attempting to broaden or carve around its claims.
• Patent thickets exist around nucleotide analog treatments, with overlapping claims around chemical structures, combination protocols, and dosing.

Litigation & Patent Challenges:

• There are no publicly documented litigations directly concerning U.S. Patent 7,632,870.
• Challenges may arise over the patent if biosimilar or generic competitors seek to innovate around its claims, especially given the age of the patent and the busy patent landscape for HCV.

---

Implications for Commercialization

• The patent provides exclusivity for Gilead’s nucleotide analog combination therapies until 2030.
• Companies developing similar HCV treatments must navigate the claims carefully, potentially designing around specific chemical modifications or combination protocols.
• The patent's claims include broad therapeutic methods that could hinder generic entry in the U.S. market for HCV nucleotide-based therapies.

Future Patent Strategies

• Filing continuation applications for broader chemical classes or new combination methods.
• Developing novel dosage forms or formulations that circumvent the specific claims.
• Patent term extensions or new filings for improved analogs.

---

Key Takeaways

• U.S. Patent 7,632,870 pioneers claims on 2'-modified nucleoside analogs for HCV treatment, covering methods, compositions, and combinations.
• The patent's broad chemical and method claims safeguard a significant portion of Gilead’s HCV nucleotide-based therapeutics pipeline until 2030.
• The patent landscape includes numerous overlapping patents, with strategic importance for both patent holders and competitors.
• Companies seeking to develop HCV nucleotide therapies must evaluate the scope of this patent carefully, especially regarding chemical structure and combination claims.
• The patent’s enforceability depends on the specific therapy design, with ongoing patent filings potentially extending the protection horizon.

---

FAQs

Q1: Does U.S. Patent 7,632,870 cover all nucleotide analogs for HCV?
No. It specifically covers certain 2'-modified nucleoside analogs used in combination or alone, with particular chemical modifications outlined in its claims.

Q2: Are combination therapies with other antivirals also protected by this patent?
Yes. The patent explicitly claims methods combining nucleotide analogs with other antiviral agents such as protease inhibitors and interferons.

Q3: How long will the patent prevent generic competition?
The patent expires in 2030, after which generic manufacturers can seek approval, assuming no other patents block entry.

Q4: Can competitors develop similar treatments by using different chemical modifications?
Potentially, if their molecules do not infringe the specific chemical structures claimed. Designing around the patent requires avoiding the exact modifications described.

Q5: What should patent applicants consider when designing nucleotide analogs for HCV?
Applicants should consider filing new patents covering novel modifications, alternative combination methods, and improved formulations to extend protection beyond current patents.

---

Sources

1. U.S. Patent and Trademark Office, Patent No. 7,632,870.
2. Gilead Sciences, Inc. Patent Portfolio Documentation.
3. FDA Drug Approval and Patent Data.
4. Patent Landscape Reports for HCV Therapeutics.
5. Industry Patent Filings and Legal Proceedings (public records).

Recent additions to Drugs Protected by US Patent 7,632,870

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Ipsen	IQIRVO	elafibranor	TABLET	218860	Jun 10, 2024	RX	Yes	7,632,870	Y

Drugs Protected by US Patent 7,632,870

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,632,870

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E364588
Australia	2003264699
Brazil	0312399